anti-LAP monoclonal antibody, antigen binding fragment thereof and application thereof
1. An anti-LAP monoclonal antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of HCDR1 of the heavy chain variable region is selected from SEQ ID NO 1, SEQ ID NO 7, SEQ ID NO 13, SEQ ID NO 19, SEQ ID NO 24 or SEQ ID NO 30; the amino acid sequence of HCDR2 in the heavy chain variable region is selected from SEQ ID NO 2, SEQ ID NO 8, SEQ ID NO 14, SEQ ID NO 20, SEQ ID NO 25 or SEQ ID NO 31; the amino acid sequence of HCDR3 in the heavy chain variable region is selected from SEQ ID NO. 3, SEQ ID NO. 9, SEQ ID NO. 15, SEQ ID NO. 21, SEQ ID NO. 26 or SEQ ID NO. 32; the amino acid sequence of LCDR1 of the light chain variable region is selected from SEQ ID NO. 4, SEQ ID NO. 10, SEQ ID NO. 16, SEQ ID NO. 22, SEQ ID NO. 27 or SEQ ID NO. 33; the amino acid sequence of LCDR2 of the light chain variable region is selected from SEQ ID NO. 5, SEQ ID NO. 11, SEQ ID NO. 17 or SEQ ID NO. 28; the amino acid sequence of LCDR3 in the light chain variable region is selected from SEQ ID NO. 6, SEQ ID NO. 12, SEQ ID NO. 18, SEQ ID NO. 23, SEQ ID NO. 29 or SEQ ID NO. 34.
2. The anti-LAP monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is selected from any one of:
a-1. the HCDR1 of the heavy chain variable region comprises an amino acid sequence shown as SEQ ID No. 1, the HCDR2 of the heavy chain variable region comprises an amino acid sequence shown as SEQ ID No. 2, the HCDR3 of the heavy chain variable region comprises an amino acid sequence shown as SEQ ID No. 3, the LCDR1 of the light chain variable region comprises an amino acid sequence shown as SEQ ID No. 4, the LCDR2 of the light chain variable region comprises an amino acid sequence shown as SEQ ID No. 5, and the LCDR3 of the light chain variable region comprises an amino acid sequence shown as SEQ ID No. 6;
a-2. the HCDR1 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 7, the HCDR2 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 8, the HCDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 9, the LCDR1 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 10, the LCDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 11, and the LCDR3 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 12;
a-3. the HCDR1 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 13, the HCDR2 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 14, the HCDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 15, the LCDR1 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 16, the LCDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 17, and the LCDR3 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 18;
a-4. the HCDR1 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 19, the HCDR2 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 20, the HCDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 21, the LCDR1 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 22, the LCDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 11, and the LCDR3 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 23;
a-5. the HCDR1 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 24, the HCDR2 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 25, the HCDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 26, the LCDR1 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 27, the LCDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 28, and the LCDR3 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 29;
a-6. the HCDR1 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 30, the HCDR2 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 31, the HCDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 32, the LCDR1 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 33, the LCDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 11, and the LCDR3 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 34.
3. The anti-LAP monoclonal antibody or antigen-binding fragment thereof of claim 2, wherein said monoclonal antibody or antigen-binding fragment thereof is selected from any one of:
a-1. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 35, and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 36;
a-2. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 37, and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 38;
a-3. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 39, and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 40;
a-4. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 41, and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 42;
a-5. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 43, and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 44;
a-6. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 45 and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 46.
4. The anti-LAP monoclonal antibody or antigen-binding fragment thereof of claim 3, further comprising a heavy chain constant region of one of murine IgG1, IgG2a, IgG3, IgG4 types;
preferably, the heavy chain constant region is murine IgG2a type.
5. A polynucleotide molecule encoding the anti-LAP monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1-4.
6. A recombinant DNA expression vector comprising the polynucleotide molecule of claim 5.
7. A host cell transfected with the recombinant DNA expression vector of claim 6, wherein said host cell comprises a prokaryotic cell, a yeast cell, an insect cell, or a mammalian cell;
preferably, the host cell is a mammalian cell, and the mammalian cell is a HEK293 cell, a CHO cell, or an NS0 cell.
8. A medicament comprising the anti-LAP monoclonal antibody or an antigen-binding fragment thereof according to any one of claims 1 to 4.
9. Use of the anti-LAP monoclonal antibody or antigen-binding fragment thereof of any one of claims 1-4 for the manufacture of a medicament for the treatment of cancer, fibrotic disease or autoimmune disease; the cancer is selected from non-small cell lung cancer, colorectal cancer, pancreatic cancer, renal cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma or glioma; the fibrotic disease includes pulmonary fibrosis or liver fibrosis; the autoimmune disease is selected from systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis, or xerosis.
10. Use of the anti-LAP monoclonal antibody or antigen-binding fragment thereof of any one of claims 1-4 in combination with an anti-PD-1 monoclonal antibody for the manufacture of a medicament for the treatment of cancer; the cancer is selected from non-small cell lung cancer, colorectal cancer, pancreatic cancer, renal cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma or glioma.
Background
Cancer immunotherapy utilizes the immune mechanism of human body to enhance the immune function of patients by active or passive methods to achieve the purpose of killing tumor cells, and the current cancer immune checkpoint inhibitor treatment achieves breakthrough progress and durable cancer immunotherapy response and gradually becomes the first-line standard treatment mode of increasing cancer treatment. However, a large number of patients with tumors do not respond to this treatment modality, suggesting that there are other mechanisms that prevent the immune system from targeting tumor cells.
In the retrospective analysis of clinical data of tumor patients, activation of TGF beta signaling pathway is found to be a key factor of immune therapy non-response, transcription map analysis of tumor biopsy samples before treatment of melanoma patients not responding to anti-PD-1 antibody treatment shows that a large amount of TGF beta related signaling pathway exists, and the same analysis is carried out on tumor samples of malignant bladder cancer patients, and the result also shows that TGF beta related transcription label has obvious correlation with anti-PD-1 therapy lack response, especially in tumors in which CD 8T cells can not enter the interior of the tumor, the clinical data are also verified in a pre-clinical mouse allogenic tumor model, and in an EMT-6 breast cancer model which has low or no response to PD-L1 treatment, the PD-L1 inhibitor and TGF beta inhibitor are combined to cause the obvious increase of tumor response proportion, the antitumor activity of this combination therapy is associated with cancer-associated fibrosis and the phenotype of activated CD8 infiltration into the tumor. Treatment with the small molecule inhibitor ALK5 in combination with a PD-L1 inhibitor and a TGF β type I receptor also produced the same effect in a mouse colon cancer model. In summary, relevant evidence of clinical origin and preclinically effective tumor suppression results indicate that drug development for inhibition of TGF signaling pathway holds great promise in clinical drug development for increasing the response rate of clinical cancer immunotherapy.
Three forms of TGF-beta 1, TGF-beta 2, TGF-beta 3, each encoded by a different gene, are present in mammals, but are all signaled by the same TGF-beta receptor complex, and all three isoforms are expressed in vivo as latent inactive protein complexes. In vivo, latent TGF β 1 and TGF β 3 are activated by α v integrin, which triggers a conformational change by acting on the RGD region on LAP (latent-associated peptide), thereby releasing active TGF β 1 and TGF β 3 factors, TGF β 1 also being released from the latent complex by proteolysis of LAP. TGF β 1 is synthesized in vivo as a precursor protein, and its mature, biologically active TGF β 1 cytokine forms small complexes with the LAP protein cage, which forms large complexes with 5 different anchor proteins (GARP, LRRC33, LTBP1, LTBP3, LTBP4) via disulfide bonds, thereby localizing TGF β 1 in different types of cells or extracellular matrices.
TGF β 1 is a multifunctional peptide molecule that controls and affects proliferation, differentiation, apoptosis and other cellular functions of a variety of cells. TGF β 1 also plays an important role in the immune system, playing different roles in different types of immune cells and cells at different developmental stages, and TGF β 1 is generally considered as an immunosuppressive factor. Most immune cells secrete TGF β 1, regulatory T cells inhibit the activity of other T cells by releasing TGF β 1, e.g., TGF β 1 inhibits the proliferation of IL-1/IL-2 dependent activated T cells; inhibit the activation of resting helper T cells, cytotoxic T cells and the like; inhibit the secretion and activity of different cytokines such as IFN-gamma, TNF-alpha and the like, and can reduce the activity of immune cells by reducing the expression level of cytokine receptors, and the TGF beta 1 has an inhibiting function on macrophages and monocytes.
Although the biological mechanisms of the TGF signaling pathway in disease are well understood, the development of therapies targeting the TGF signaling pathway is fraught with challenges. ALK5 small molecule inhibitors targeting TGF β type I receptor kinases or antibodies that simultaneously block three isoforms TGF β 1, TGF β 2, TGF β 3 exhibit severe valvular cardiovirulence in mice, rats, and dogs, meaning that broad-spectrum inhibition of one or more isoform-driven signaling pathways would limit the clinical benefit of such drugs. LAP is a protein cage of TGF beta 1, mature TGF beta 1 is locked in a latent compound, a medicine acting on a LAP target can regulate and control the release or inhibition of TGF beta 1 by regulating a LAP-TGF beta 1 compound structure, so that the activity path mediated by TGF beta 1 is regulated and controlled, the same variety of medicines are not available in the market at home and abroad at present, and in order to meet market demands, the development of an anti-LAP monoclonal antibody, an antigen binding fragment thereof and the application thereof, which can regulate and control the release of TGF beta 1 and improve the tumor microenvironment, are urgently needed.
Disclosure of Invention
In order to solve the problems in the prior art, the invention discloses an anti-LAP monoclonal antibody, an antigen binding fragment thereof and application thereof, wherein the anti-LAP monoclonal antibody can inhibit the release of TGF beta 1 from a source, delete suppressive T cells and improve tumor immune response.
The specific technical scheme of the invention is as follows:
the invention provides an anti-LAP monoclonal antibody or an antigen binding fragment thereof, which comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of HCDR1 of the heavy chain variable region is selected from SEQ ID NO 1, SEQ ID NO 7, SEQ ID NO 13, SEQ ID NO 19, SEQ ID NO 24 or SEQ ID NO 30; the amino acid sequence of HCDR2 in the heavy chain variable region is selected from SEQ ID NO 2, SEQ ID NO 8, SEQ ID NO 14, SEQ ID NO 20, SEQ ID NO 25 or SEQ ID NO 31; the amino acid sequence of HCDR3 in the heavy chain variable region is selected from SEQ ID NO. 3, SEQ ID NO. 9, SEQ ID NO. 15, SEQ ID NO. 21, SEQ ID NO. 26 or SEQ ID NO. 32; the amino acid sequence of LCDR1 of the light chain variable region is selected from SEQ ID NO. 4, SEQ ID NO. 10, SEQ ID NO. 16, SEQ ID NO. 22, SEQ ID NO. 27 or SEQ ID NO. 33; the amino acid sequence of LCDR2 of the light chain variable region is selected from SEQ ID NO. 5, SEQ ID NO. 11, SEQ ID NO. 17 or SEQ ID NO. 28; the amino acid sequence of LCDR3 in the light chain variable region is selected from SEQ ID NO. 6, SEQ ID NO. 12, SEQ ID NO. 18, SEQ ID NO. 23, SEQ ID NO. 29 or SEQ ID NO. 34.
Further, the monoclonal antibody or antigen binding fragment thereof is selected from any one of the following:
a-1. the HCDR1 of the heavy chain variable region comprises an amino acid sequence shown as SEQ ID No. 1, the HCDR2 of the heavy chain variable region comprises an amino acid sequence shown as SEQ ID No. 2, the HCDR3 of the heavy chain variable region comprises an amino acid sequence shown as SEQ ID No. 3, the LCDR1 of the light chain variable region comprises an amino acid sequence shown as SEQ ID No. 4, the LCDR2 of the light chain variable region comprises an amino acid sequence shown as SEQ ID No. 5, and the LCDR3 of the light chain variable region comprises an amino acid sequence shown as SEQ ID No. 6;
a-2. the HCDR1 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 7, the HCDR2 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 8, the HCDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 9, the LCDR1 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 10, the LCDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 11, and the LCDR3 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 12;
a-3. the HCDR1 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 13, the HCDR2 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 14, the HCDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 15, the LCDR1 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 16, the LCDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 17, and the LCDR3 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 18;
a-4. the HCDR1 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 19, the HCDR2 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 20, the HCDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 21, the LCDR1 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 22, the LCDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 11, and the LCDR3 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 23;
a-5. the HCDR1 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 24, the HCDR2 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 25, the HCDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 26, the LCDR1 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 27, the LCDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 28, and the LCDR3 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 29;
a-6. the HCDR1 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 30, the HCDR2 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 31, the HCDR3 of the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 32, the LCDR1 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 33, the LCDR2 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 11, and the LCDR3 of the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 34.
Further, the monoclonal antibody or antigen binding fragment thereof is selected from any one of the following:
a-1. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 35, and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 36;
a-2. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 37, and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 38;
a-3. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 39, and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 40;
a-4. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 41, and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 42;
a-5. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 43, and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 44;
a-6. the heavy chain variable region comprises the amino acid sequence shown as SEQ ID No. 45 and the light chain variable region comprises the amino acid sequence shown as SEQ ID No. 46.
Further, the monoclonal antibody or antigen binding fragment thereof further comprises a heavy chain constant region, wherein the heavy chain constant region is one of mouse IgG1, IgG2a, IgG3 and IgG 4;
preferably, the heavy chain constant region is murine IgG2a type.
The invention also provides a polynucleotide molecule encoding the anti-LAP monoclonal antibody or antigen-binding fragment thereof.
The invention also provides a recombinant DNA expression vector which comprises the polynucleotide molecule.
The invention also provides a host cell for transfecting the recombinant DNA expression vector, wherein the host cell comprises a prokaryotic cell, a yeast cell, an insect cell or a mammalian cell;
preferably, the host cell is a mammalian cell, and the mammalian cell is a HEK293 cell, a CHO cell, or an NS0 cell.
The invention also provides a medicament comprising the anti-LAP monoclonal antibody or an antigen-binding fragment thereof.
The invention also provides the application of the anti-LAP monoclonal antibody or the antigen binding fragment thereof in preparing medicaments for treating cancers, fibrotic diseases or autoimmune diseases; the cancer is selected from non-small cell lung cancer, colorectal cancer, pancreatic cancer, renal cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma or glioma; the fibrotic disease includes pulmonary fibrosis or liver fibrosis; the autoimmune disease is selected from systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis, or xerosis.
The invention also provides the application of the combination of the anti-LAP monoclonal antibody or the antigen binding fragment thereof and the anti-PD-1 monoclonal antibody in preparing a medicament for treating cancer; the cancer is selected from non-small cell lung cancer, colorectal cancer, pancreatic cancer, renal cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma or glioma.
The invention has the following beneficial effects: the anti-LAP monoclonal antibody provided by the invention can inhibit the release of TGF beta 1 from the source, delete suppressive T cells and improve tumor immune response, can be combined with various immunotherapy drugs for application, can be expanded to more types of cancers, autoimmune diseases and fibrotic diseases, and has huge clinical requirements and huge market potential; cancer selected from, but not limited to, non-small cell lung cancer, colorectal cancer, pancreatic cancer, renal cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma, or glioma; fibrotic diseases including pulmonary fibrosis or liver fibrosis; the autoimmune disease is selected from systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis, or xerosis.
Drawings
FIG. 1 is a plasmid map of pScFv-Disb-HS vector in example 3 of the present invention;
FIG. 2 is a graph showing a comparison of relative affinities of anti-LAP phage monoclonal antibodies by gradient dilution ELISA in example 4 of the present invention;
FIG. 3 is a map of the vector pTSE in example 5 of the present invention;
FIG. 4 is a graph showing a comparison of the binding ability of an anti-LAP monoclonal antibody to an antigen LAP in example 6 of the present invention;
FIG. 5 is a competition curve of an anti-LAP monoclonal antibody and a positive antibody in example 7 of the present invention;
FIG. 6 is a graph showing a comparison of the binding ability of an anti-LAP monoclonal antibody to cells expressing LAP on the surface in example 8 of the present invention;
FIG. 7 is a graph showing that an anti-LAP monoclonal antibody inhibits the release of cell surface TGF-beta 1 in example 10 of the present invention;
FIG. 8 is a graph showing the tumor-suppressing effect of the anti-LAP monoclonal antibody (administered alone) in a mouse colon cancer model in example 11 of the present invention;
FIG. 9 is a graph showing the tumor-inhibiting effect of an anti-LAP monoclonal antibody (administered in combination with an anti-PD-1 antibody) in a mouse colon cancer model in example 12 of the present invention;
FIG. 10 is a graph showing survival rate of each group of mice in example 12 of the present invention.
Detailed Description
In order that the invention may be more readily understood, some technical and scientific terms of the invention are set forth below before the examples are described:
the term "LAP (latent-associated peptide)" as used herein, is a portion of the polypeptide sequence at the N-terminus of the TGF β precursor protein. TGF-beta precursor protein is synthesized in vivo, and then is decomposed into mature TGF-beta cell factor with bioactivity and LAP protein, the latter is in a cage shape to wrap TGF-beta in to form a small compound, and forms a large compound with 5 different anchoring proteins through disulfide bonds, so that TGF-beta is limited in different types of cells or extracellular matrix; when LAP is hydrolyzed by protease or its RGD domain is structurally changed, TGF β is released from the latent complex, exhibiting its cytokine activity.
The term "antibody" as used herein encompasses whole antibodies and any antigen-binding fragment thereof, including murine, humanized, bispecific or chimeric antibodies, which may also be Fab, F (ab)2, Fv or ScFv (single chain antibody), which may be naturally occurring antibodies or antibodies which may be altered (e.g., mutated, deleted, substituted, etc.).
As used herein, the terms "variable region" and "constant region", i.e., the regions of the heavy and light chains of an antibody near the N-segment are variable regions (V regions), the remaining amino acid sequences near the C-segment are relatively stable, and are constant regions (C regions), the variable regions include 3 Complementarity Determining Regions (CDRs) and 4 Framework Regions (FRs), each of the light and heavy chain variable regions consists of 3 CDR regions and 4 FR regions, the 3 CDR regions of the heavy chain are represented by HCDR1, HCDR2 and HCDR3, respectively, and the 3 CDR regions of the light chain are represented by LCDR1, LCDR2 and LCDR3, respectively.
The term "antibody molecule" as used herein, the source thereof is an antibody obtained by immunizing a mouse with a LAP antigen.
The term "CHO cell" is a chinese hamster ovary cell (chinese hamster ovary cell); the term "HEK 293 cells" was human embryonic kidney 293E cells (human embryo kidney 293E cells), and the term "NS 0 cells" was mouse NS0 thymoma cells.
The present invention will be described in further detail with reference to the following examples.
Example 1
The embodiment 1 of the invention provides an anti-LAP monoclonal antibody or an antigen-binding fragment thereof, which comprises a heavy chain variable region and a light chain variable region, wherein the amino acid sequence of HCDR1 of the heavy chain variable region is selected from SEQ ID NO 1, SEQ ID NO 7, SEQ ID NO 13, SEQ ID NO 19, SEQ ID NO 24 or SEQ ID NO 30; the amino acid sequence of HCDR2 in the heavy chain variable region is selected from SEQ ID NO 2, SEQ ID NO 8, SEQ ID NO 14, SEQ ID NO 20, SEQ ID NO 25 or SEQ ID NO 31; the amino acid sequence of HCDR3 in the heavy chain variable region is selected from SEQ ID NO. 3, SEQ ID NO. 9, SEQ ID NO. 15, SEQ ID NO. 21, SEQ ID NO. 26 or SEQ ID NO. 32; the amino acid sequence of LCDR1 of the light chain variable region is selected from SEQ ID NO. 4, SEQ ID NO. 10, SEQ ID NO. 16, SEQ ID NO. 22, SEQ ID NO. 27 or SEQ ID NO. 33; the amino acid sequence of LCDR2 of the light chain variable region is selected from SEQ ID NO. 5, SEQ ID NO. 11, SEQ ID NO. 17 or SEQ ID NO. 28; the amino acid sequence of LCDR3 in the light chain variable region is selected from SEQ ID NO. 6, SEQ ID NO. 12, SEQ ID NO. 18, SEQ ID NO. 23, SEQ ID NO. 29 or SEQ ID NO. 34.
Example 2
In the embodiment 2 of the invention, a mouse is immunized by using the LAP antigen, an immunization method is optimized, a phage display library is created, an anti-LAP monoclonal antibody is obtained, and the anti-LAP monoclonal antibody or an antigen binding fragment thereof obtained by screening is selected from any one of the following substances:
example 3
Embodiment 3 of the present invention provides a screening method for anti-LAP single-chain antibody specifically based on embodiment 2, as follows: the method comprises the following steps: mice immunized with LAP antigens
1. Experimental animals:
species lines: BALB/c, female, mouse; weight: 18-20 g;
experimental animal providers: beijing Huafukang Biotechnology GmbH.
2. Immunization: the mice are immunized, and the immune antigen is human LAP (Nanjing Kingsrey Biotechnology Co., Ltd., synthesis gene, construction vector of the company, expression and purification).
Step two: construction of phage antibody libraries
Taking mouse spleen cells with higher titer, extracting total RNA in the mouse spleen cells by using Trizol reagent (purchased from Ambion, the cargo number is 15596026), obtaining cDNA by RT-PCR, using the cDNA as a template, using degenerate primers (used degenerate primer reference: Journal of Immunological Methods233(2000) 167-. The transformed vector is named pScFv-Disb-HS vector, the obtained plasmid map is shown in figure 1, and a mouse immune phage antibody library is constructed on the basis of the vector.
Step three: and (3) coating the immune tube with LAP (lipocalin) as an antigen in an amount of 4 mug/500 mug/tube at 4 ℃ overnight, respectively sealing the immune tube and the immune phage antibody library with 4% skimmed milk powder/PBST, and sealing at room temperature for 1 h. Adding the sealed immune phage antibody library into an immune tube for antigen-antibody combination, wherein the input amount of the phage is about 109～1012After 1 hour of reaction at room temperature, unbound phage was washed off with PBST-PBS, eluted with 0.1M Glycine-HCl pH2.2, and the eluted phage antibody solution was neutralized to pH7.0 or so with 1.5M Tris-HCl pH 8.8.
Step four: and infecting 10ml of TG1 bacterial solution growing to the logarithmic phase with the neutralized phage, standing in an incubator at 37 ℃ for 30min, taking out part of the bacterial solution, performing gradient dilution, and coating on a 2YTAG plate for calculating the output of the phage. The remaining bacterial solution was centrifuged and the supernatant discarded, and the pellet was resuspended in a small volume of medium, aspirated and plated on a 2YTAG large plate in preparation for the next round of screening.
Step five: scraping the infected and plated thallus from a large plate, inoculating the thallus to a 2YTAG liquid culture medium, shaking to a logarithmic phase, adding M13KO7 to assist the superinfection of the phage, culturing at the temperature of 28 ℃ and the rpm of 220 overnight to prepare the phage, and performing PEG/NaCl sedimentation purification on the phage for the next round of screening, and performing one round of enrichment screening of a phage library.
Step six: screening of LAP phage single-chain antibody positive clones: after one round of screening, well-separated monoclonal colonies were picked, inoculated into a 96-well deep-well plate containing 2YTAG liquid medium, cultured at 37 ℃ and 220rpm to its logarithmic growth phase, and added to about 10/well10The helper phage M13KO7 was quiescently infected at 37 ℃ for 30 min. 4000rpm, centrifugation for 15min, discarding supernatant, bacterial body with 2YTAK heavy suspension precipitation, at 28 degrees C and 220rpm under conditions of overnight culture. Centrifuging at 4000rpm and 4 ℃ for 15min, sucking amplified phage supernatant for ELISA identification, finally screening to obtain six anti-LAP monoclonal antibody molecules with higher affinity, which are respectively named as A-1, A-2, A-3, A-4, A-5 and A-6, performing gene sequencing on the obtained monoclonal antibody to determine a correct antibody sequence, and performing sequencing to obtain the 6 screened monoclonal antibody sequences as follows:
antibody molecules
Heavy chain variable region sequence
Light chain variable region sequence
A-1
SEQ ID No:35
SEQ ID No:36
A-2
SEQ ID No:37
SEQ ID No:38
A-3
SEQ ID No:39
SEQ ID No:40
A-4
SEQ ID No:41
SEQ ID No:42
A-5
SEQ ID No:43
SEQ ID No:44
A-6
SEQ ID No:45
SEQ ID No:46
Specifically, SEQ ID No. 35 (amino acid sequence of the heavy chain variable region of A-1);
EVQLEQSGPELKKPGETVKISCKASGYTFTSYGMNWVKQAPGKALKWMGWINTYTGEPTYADDFKGRFAYSLEATANTAYLQIYNLKNEDTATYFCARSGRYTRPLYYIMDFWGQGTSVTVSS；
SEQ ID No. 36 (amino acid sequence of the light chain variable region of A-1);
DIVLTQSPASLAVSLGQRATISCKASQSVDYDGNSYMNWHQQKPGQPPKLLIYGASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPWTFGGGTKLEIK；
37 (amino acid sequence of heavy chain variable region of A-2);
EVQLEESGAELVRSGASVKLSCTASGFNFNDYYMHWVKQRPEQGLEWIGWIDPENGDTEYAPKFQVKATMTADTSSNTAYLHLSSLASEDTAVYYCNTPTEDMDYWGQGTSVTVSS；
38 (amino acid sequence of the light chain variable region of A-2);
DIVMTQSPSSLAVSAGEKVTMSCKSSQSLFNSRTRKNYLAWYQQKPGQSPKLLIYWASTRGSGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLLTFGAGTKLELK；
39 (amino acid sequence of heavy chain variable region of A-3);
EVKLQESGAELVMPGASVKMSCKASGYTFTDYWMHWVKQRPGQGLEWIGAIDTSDSYTSYNQKFKGKATLTVDESSSTAYMQLSSLTSEDSAVYYCARKALSGYFDVWGAGTTVTVSS；
40 (amino acid sequence of the light chain variable region of A-3);
DIVLTQTPSSLSASLGGKVTITCKASQDIYKYIAWYQHKPGKGPRLLIHYTSTLQPGIPSRFSGSGSGRDYSFSISNLEPEDIATYYCLQYDNLRTFGGGTKLEIK；
41 (amino acid sequence of heavy chain variable region of A-4);
EVKLQESGPGLVAPSQSLSITCTVSGFSLTTYGVSWVRQPPGKGLEWLGIIWGDGTTIYQSGLISRLSISKDDSKSQVFLKLSSLQTDDTATYYCAKHYFVMDYWGQGTSVTVSS；
42 (amino acid sequence of the light chain variable region of A-4);
DIVLTQSPSSLAVSAGEKVTMNCKSSQSLLNSRIRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLWTFGGGTKLEIK；
43 (amino acid sequence of heavy chain variable region of A-5);
EVQLQQSGAVLVRPGDSVKLSCKASGYSFTRSWINWVKQRPGQGLEWIGNIYPSDSYTNYNQKFKDKATLTVDKSSSTAYMQLRSPTSEDSAVYYCTNYYLYYFDYWGQGTTLTVSSAKTTPPSVY；
44 (amino acid sequence of the light chain variable region of A-5);
DIVLTQSPSSLAVSTGEKVTMSCKSSQSLLNSRTRKSYLAWYQQKPGQSPKLLIYWTSIRESGVPDRFTGNGSGTDFTLTISSVQAEDLAVYYCKQSYNLFTFGGGTKLEMKRADAAPTVS；
45 (amino acid sequence of heavy chain variable region of A-6);
QVKLQESGPELVKPGASVKISCKASGYTFTDYNMHWVKQSHGKSLEWIGYFYPYNGGTGYKQKFKSKATLTVDNSSSTAYMELRSLTSEDSAVYYCARNHYYYYAMDYWGQGTSVTVSS；
46 (amino acid sequence of the light chain variable region of A-6);
DIVMTQTPSSLAVSAGEKVTMSCKSSQSLLNSRTRKNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCKQSYNLPWTFGGGTKLEIK。
example 4 gradient dilution ELISA comparison of the affinity of anti-LAP phage monoclonal antibodies
LAP was coated with carbonate buffer solution of ph9.6 at 50 ng/well/100 μ l, overnight at 4 ℃, washed three times with PBST, and 6 phage monoclonal antibodies obtained by screening in example 3 and a positive control anti-LAP monoclonal antibody 28G11 (the antibody is selected from patent application No. US20190144549a1, patent name anti-LAP antibody and its use) were diluted with PBST in a three-fold gradient, 100 μ l of the diluted sample was added to each well, and allowed to stand at room temperature for 1 hour. The ELISA plate was washed with PBST, and the HRP-anti-M13 monoclonal antibody diluted with PBST was added to the ELISA plate and left at room temperature for 1 h. Developing with TMB color development kit at room temperature for 10 min, and performing color development with 2M H2SO4After termination, the antigen-antibody binding curves were made using GraphPad Prism 5.0 mapping software, reading at 450nm/630nm, as shown in fig. 2, and the corresponding EC50 values were calculated as follows:
cloning
A-1
A-2
A-3
A-4
A-5
A-6
28G11
EC50
0.0188
0.0634
0.0878
0.3102
0.0603
0.1559
0.0692
From the above data and as shown in FIG. 2, all of the 6 different monoclonal antibody molecules selected in example 2 were able to bind LAP with an affinity close to that of anti-LAP monoclonal antibody 28G11, but anti-LAP monoclonal antibody A-1 had a higher affinity than the positive control anti-LAP monoclonal antibody 28G 11.
Example 5
The embodiment 5 of the present invention further defines that the anti-LAP monoclonal antibody or the antigen binding fragment thereof further comprises a heavy chain constant region based on the embodiment 3, wherein the heavy chain constant region is one of mouse IgG1, IgG2a, IgG3 and IgG 4;
preferably, the heavy chain constant region is murine IgG2a type; the amino acid sequence of the heavy chain constant region of the mouse IgG2a type is shown as SEQ ID No. 47; the specific sequence is as follows:
SEQ ID No. 47 (murine IgG2a type heavy chain constant region sequence)
AKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK。
The anti-LAP monoclonal antibody of example 4 was selected for the preparation of full antibodies, the method of antibody preparation being as follows:
1. the genes encoding the heavy chain VH and light chain VL of the 6 anti-LAP monoclonal antibodies selected in example 3 and the positive control anti-LAP monoclonal antibody 28G11 were cloned into a heavy chain and a light chainThe light chain constant region gene vector pTSE (shown in figure 3), the heavy chain constant region is preferably mouse IgG2a type constant region (the amino acid sequence is shown in SEQ ID No: 47), and the light chain constant regions are all murine CkThe chain (amino acid sequence is shown in SEQ ID No: 48), the structure of pTSE vector is shown in FIG. 3 (see page 3, 0019 of CN103525868A description for preparation process of pTSE vector]Segment).
SEQ ID No. 48 (murine C)kLight chain constant region of the chain)
ADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC；
2. HEK293E cells (purchased from the institute of basic medicine of Chinese academy of medical sciences, with the product number GNHu43) are transiently transfected, antibody expression is carried out, cell shaking culture is carried out for 3-4 days, cell supernatant is collected, and purification is carried out by a proteinA A column, so that the purified full antibody is obtained.
Example 6 binding experiment of anti-LAP monoclonal antibody to antigen LAP
Coating LAP-TGF beta 1 antigen with carbonate buffer solution with pH9.6 at 50 ng/well/100 mu l, and coating at 4 ℃ overnight; washing with 300. mu.l/well PBST five times, adding 100. mu.l blocking solution containing 2% BSA-PBST, and blocking at 37 ℃ for 2 hours; discarding the liquid in the plate, washing three times with PBST, and patting dry the test plate on a paper towel; adding anti-LAP monoclonal antibodies A-1, A-2, A-3, A-4, A-5 and A-6 and a positive control antibody 28G11 with different dilution concentrations, wherein the initial highest concentration of the antibodies is 10 mu G/ml, respectively diluting the antibodies by 5 times of concentration gradient, setting 7 concentration gradients for each antibody, and incubating the antibodies for 1h at the temperature of 37 ℃; discard the liquid in the plate, wash three times with 300. mu.l/well PBST, pat dry the test plate on paper towel; diluting a secondary antibody (HRP-anti mIg,1:2000) by using a confining liquid, adding 100 mu l of ELISA detection plate into each hole, and standing for 1 hour at room temperature in a dark place; discarding the liquid in the plate, washing three times with PBST, and patting dry the test plate on a paper towel; adding prepared ABTS substrate solution (purchased from Thermo, cat # 002024) to develop color, 100 μ l per well, developing color at room temperature for 10-30min, and then developing with 2MH2SO4The color development was terminated. Reading at 450nm/630nm, and using GraphPad Prism 5.0 mapping software to make antigen-antibody binding curvesThe line graph, as shown in fig. 4, and the corresponding EC50 values were calculated, with the following specific data:
as can be seen from the above data and FIG. 4, all of the 6 selected monoclonal antibodies were able to bind LAP, and the anti-LAP monoclonal antibody A-1 in the 6 antibody molecules had the smallest EC50 value and was smaller than the positive control antibody 28G11, indicating that it had the best ability to bind LAP.
Example 7 competition experiment of anti-LAP monoclonal antibody with antigen LAP
Coating LAP-TGF beta 1 antigen with carbonate buffer solution with pH9.6 at 50 ng/well/100 mu l, and coating at 4 ℃ overnight; washing with 300. mu.l/well PBST five times, adding 100. mu.l blocking solution containing 2% BSA-PBST, and blocking at 37 ℃ for 2 hours; discarding the liquid in the plate, washing three times with PBST, and patting dry the test plate on a paper towel; add 50. mu.l of 28G11 labeled with Biotin using Sulfo-NHS-LC-Biotin reagent (purchased from thermo, cat. No. 1854210), add anti-LAP monoclonal antibodies A-1, A-2, A-3, A-4, A-5 and A-6 and positive control antibody 28G11 at various dilution concentrations; the concentration of 28G11 labeled by biotin in the system is 1 mug/ml, the initial highest concentration of seven antibodies is 10 mug/ml, after 5 times of concentration gradient dilution, each antibody is provided with 7 concentration gradients, and incubation is carried out for 1h at the temperature of 37 ℃; discard the liquid in the plate, wash three times with 300. mu.l/well PBST, pat dry the test plate on paper towel; diluting a secondary antibody (HRP-anti mIg,1:2000) by using a confining liquid, adding 100 mu l of ELISA detection plate into each hole, and standing for 1 hour at room temperature in a dark place; discarding the liquid in the plate, washing three times with PBST, and patting dry the test plate on a paper towel; adding prepared ABTS substrate solution (purchased from Thermo, cat # 002024) to develop color, 100 μ l per well, developing color at room temperature for 10-30min, and then developing with 2MH2SO4The color development was terminated. Read at 450nm/630nmThe antibody competition graph was generated using GraphPad Prism 5.0 mapping software, as shown in fig. 5, and the corresponding IC50 values were calculated as follows:
cloning
A-1
A-2
A-3
A-4
A-5
A-6
28G11
IC50(ng/ml)
97.2
76.4
6.95
8.05
52.6
55.7
361
From the above data and FIG. 5, it is clear that 6 different monoclonal antibodies are able to compete with 28G 11. Wherein the competitive inhibition rates of the anti-LAP monoclonal antibodies A-1, A-2, A-5 are very close to 28G11 and the IC50 value is lower than 28G11, indicating that they are effective in blocking the binding of 28G11 to antigen, thereby inferring that their antigen binding sites may be adjacent to, overlapping with, or even identical to the antigen binding site of 28G 11.
Example 8 binding experiment of anti-LAP monoclonal antibody to cells expressing LAP on the surface
CHO cells overexpressing LAP-TGF beta 1 at 2x 105Individual cells/well were seeded into 96-well plates. The initial concentrations of the anti-LAP monoclonal antibodies A-1, A-2, A-5 and the positive control antibody 28G11 were set to 200. mu.g/ml, diluted in 5-fold gradients, and the cells were added to 100. mu.l/well for incubation for one hour, followed by addition of FITC-labeled goat anti-mouse fluorescent antibody (purchased from southern biotech, cat. No.: 1030-02) for flow assay detection, and cell binding curves were generated using GraphPad Prism 5.0 mapping software, the results of which are shown in FIG. 6.
The results show that the anti-LAP monoclonal antibodies A-1, A-2, A-5 and the positive control antibody 28G11 can be combined with cells expressing LAP on the surface, wherein the A-1 antibody and the positive control antibody 28G11 have the strongest combination ability with the LAP protein in the natural state.
Example 9
The embodiment 9 of the invention also provides a polynucleotide molecule, and an anti-LAP monoclonal antibody or an antigen-binding fragment thereof coded by the polynucleotide molecule.
The invention also provides a recombinant DNA expression vector, and a polynucleotide molecule contained in the recombinant DNA expression vector.
The invention also provides a host cell of the transfected recombinant DNA expression vector, wherein the host cell comprises prokaryotic cells, yeast cells, insect cells or mammalian cells;
preferably, the host cell is a mammalian cell, and the mammalian cell is a HEK293 cell, a CHO cell, or an NS0 cell.
The invention also provides a medicament comprising an anti-LAP monoclonal antibody or antigen-binding fragment thereof.
The invention also provides the application of the anti-LAP monoclonal antibody or the antigen binding fragment thereof in preparing medicaments for treating cancers, fibrotic diseases or autoimmune diseases; preferably, the cancer is selected from: non-small cell lung cancer, colorectal cancer, pancreatic cancer, renal cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma, or glioma; fibrotic diseases including pulmonary fibrosis or liver fibrosis; the autoimmune disease is selected from systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis, or xerosis.
The invention also provides the application of the combination of the anti-LAP monoclonal antibody or the antigen binding fragment thereof and the anti-PD-1 monoclonal antibody in preparing a medicament for treating cancer; the anti-PD-1 monoclonal antibody is selected from Nivolumab, Pembrolizumab, Terepril monoclonal antibody, Xindilizumab, tirezizumab, Carrilizumab or DFPD1-9, DFPD1-10, DFPD1-11, DFPD1-12 or DFPD1-13 disclosed in patent document with patent number ZL201510312910.8 and patent name of one anti-PD-1 monoclonal antibody and an obtaining method thereof, and is not limited to the above definition of the anti-PD-1 monoclonal antibody, but also can be other anti-PD-1 monoclonal antibodies commercially used in experiments, as long as the monoclonal antibody targeting PD-1 is all, and the other anti-PD-1 monoclonal antibodies are not particularly limited.
In the present invention, the anti-PD-1 monoclonal antibody is preferably DFPD1-9, DFPD1-10, DFPD1-11, DFPD1-12 or DFPD1-13 disclosed in patent No. ZL201510312910.8, a monoclonal antibody having a patent name of anti-PD-1 and a method for obtaining the same. Preferably, the cancer is selected from: non-small cell lung cancer, colorectal cancer, pancreatic cancer, renal cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma, or glioma.
Example 10 purified full anti-format functional antibodies inhibit the release of cell surface TGF-beta 1
One day ahead of time 50. mu.l (1X 10) of a cell line overexpressing LAP-TGF-. beta.1 was inoculated6Individual cells/ml) in a 96-well plate and incubated overnight with a series of concentration-gradient dilutions of 50 μ l of the total anti-LAP monoclonal antibodies a-1, a-2, a-5 and the positive control antibody 28G11, starting at 20 μ G/ml, followed by 3-fold concentration-gradient dilutions, each antibody being set to a total of 7 concentration gradients. The next day 50. mu.l (1X 10) was added6Individual cells/ml) of stable PAI-LUC-expressing mink lung epitheliumCells (purchased from the center for cell resources of the institute of basic medicine, academy of Chinese medical sciences, cat # 3111C0001CCC000195), were incubated in a cell culture chamber for 6 hours and then tested for luciferase activity, and a graph pad Prism 5.0 mapping software was used to generate an inhibition curve of the release of TGF β 1 by the antibody, as shown in FIG. 7, and corresponding IC50 values were calculated as follows:
cloning
A-1
A-2
A-5
28G11
IgG isotype
IC50(μg/ml)
0.741
NA
1.69
0.626
NA
The results show that both antibodies A-1 and A-5 can effectively inhibit the release of cell surface TGF beta 1, especially the A-1 antibody, the IC50 value of the A-1 antibody is close to that of the positive control antibody 28G11, and the release of TGF beta 1 is slightly more inhibited under the same concentration than that of the positive control antibody 28G 11.
EXAMPLE 11 in vivo tumor inhibition assay with Single administration
1. Experimental animals:
species lines: BALB/c, female, mouse; the week age is as follows: 6-8 weeks;
experimental animal providers: beijing Huafukang Biotechnology GmbH.
2. The experimental method comprises the following steps:
each mouse was inoculated subcutaneously in the right dorsal part 3 x 105CT26 tumor cells (purchased from ATCC; cat number: CRL-2638) are randomly divided into a plurality of groups after tumorigenesis, each group is 10, 3 days later, intraperitoneal injection is carried out on the anti-LAP monoclonal antibody A-1(10mg/kg) provided by the invention, a positive control group (10mg/kg) with the same amount of positive control antibody 28G11 for positive illumination injection is arranged, the same amount of isotype IgG (10mg/kg) is injected on the negative control group, the tumor volume is measured twice a week, three times a week and once a week the body weight is measured, the tumor growth condition is observed and recorded, and the tumor volume exceeds 3000mm3The mice were sacrificed by cervical dislocation, and the tumors were carefully isolated with surgical scissors and weighed, and the results are shown in fig. 8.
As can be seen from fig. 8, the tumor volumes of the injection experimental group and the positive control group are equivalent and smaller than that of the negative control group. However, the standard deviation of each group was large due to the large difference in tumor volume between mice in the same group, and the efficacy of the anti-LAP monoclonal antibodies A-1 and 28G11 was not significant. Considering that one goal of this project was to improve tumor immune response, the next step was to verify that tumor suppression experiments were performed in combination with PD-1 administration.
EXAMPLE 12 Combined in vivo tumor inhibition assay
1. Experimental animals:
species lines: BALB/c, female, mouse; the week age is as follows: 6-8 weeks;
experimental animal providers: beijing Huafukang Biotechnology GmbH.
2. Different administration groups are set, specifically as follows:
an anti-mouse PD-1 monoclonal antibody (purchased from Bio X Cell, cat # BE0146) single-dose group, an anti-LAP monoclonal antibody A-1 single-dose group (10mg/kg), an anti-LAP monoclonal antibody A-1 combination anti-mouse PD-1 antibody dose group (10mg/kg) and an isotype IgG control group (10 mg/kg);
the experimental procedure was the same as in example 11, and each mouse was inoculated subcutaneously into the right dorsal part 3 x 105The tumor cells of CT26 are divided into several groups, each group contains 10 tumor cells, the administration group is injected into abdominal cavity after 3 days, the administration is carried out twice every week, the tumor volume is measured three times every week and the body weight is measured once a week, the tumor growth condition is observed and recorded, and the tumor volume exceeds 3000mm3The mice were sacrificed by cervical dislocation, and tumors were carefully isolated with surgical scissors and weighed. The results are shown in FIGS. 9 and 10.
As can be seen from FIG. 9, the PD-1 antibody group showed substantially no tumor-suppressing effect compared with the control group, which is consistent with the insensitivity of colon cancer to PD-1 antibody in the literature. Compared with a PD-1 antibody group, the combined medicine group shows remarkable tumor inhibition effect; compared with the group administered with the antibody A-1 alone, the composition also shows a certain tumor inhibition effect. As can be seen from FIG. 10, from the survival curve, the combination group showed significant tumor suppression effect compared to the group of PD-1 antibody or the group of A-1 antibody administered alone.
The present invention is not limited to the above-mentioned preferred embodiments, and any other products in various forms can be obtained by anyone in the light of the present invention, but any changes in the shape or structure thereof, which have the same or similar technical solutions as those of the present application, fall within the protection scope of the present invention.
Sequence listing
<110> Beijing Oriental Baitai Biotechnology GmbH
<120> anti-LAP monoclonal antibody, antigen binding fragment thereof and application thereof
<160> 48
<170> SIPOSequenceListing 1.0
<210> 1
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 1
Gly Tyr Thr Phe Thr Ser Tyr Gly
1 5
<210> 2
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 2
Ile Asn Thr Tyr Thr Gly Glu Pro
1 5
<210> 3
<211> 16
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 3
Ala Arg Ser Gly Arg Tyr Thr Arg Pro Leu Tyr Tyr Ile Met Asp Phe
1 5 10 15
<210> 4
<211> 10
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 4
Gln Ser Val Asp Tyr Asp Gly Asn Ser Tyr
1 5 10
<210> 5
<211> 3
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 5
Gly Ala Ser
1
<210> 6
<211> 9
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 6
Gln Gln Ser Asn Glu Asp Pro Trp Thr
1 5
<210> 7
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 7
Gly Phe Asn Phe Asn Asp Tyr Tyr
1 5
<210> 8
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 8
Ile Asp Pro Glu Asn Gly Asp Thr
1 5
<210> 9
<211> 10
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 9
Cys Asn Thr Pro Thr Glu Asp Met Asp Tyr
1 5 10
<210> 10
<211> 12
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 10
Gln Ser Leu Phe Asn Ser Arg Thr Arg Lys Asn Tyr
1 5 10
<210> 11
<211> 3
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 11
Trp Ala Ser
1
<210> 12
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 12
Lys Gln Ser Tyr Asn Leu Leu Thr
1 5
<210> 13
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 13
Gly Tyr Thr Phe Thr Asp Tyr Trp
1 5
<210> 14
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 14
Ile Asp Thr Ser Asp Ser Tyr Thr
1 5
<210> 15
<211> 11
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 15
Ala Arg Lys Ala Leu Ser Gly Tyr Phe Asp Val
1 5 10
<210> 16
<211> 6
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 16
Gln Asp Ile Tyr Lys Tyr
1 5
<210> 17
<211> 3
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 17
Tyr Thr Ser
1
<210> 18
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 18
Leu Gln Tyr Asp Asn Leu Arg Thr
1 5
<210> 19
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 19
Gly Phe Ser Leu Thr Thr Tyr Gly
1 5
<210> 20
<211> 7
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 20
Ile Trp Gly Asp Gly Thr Thr
1 5
<210> 21
<211> 9
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 21
Ala Lys His Tyr Phe Val Met Asp Tyr
1 5
<210> 22
<211> 12
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 22
Gln Ser Leu Leu Asn Ser Arg Ile Arg Lys Asn Tyr
1 5 10
<210> 23
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 23
Lys Gln Ser Tyr Asn Leu Trp Thr
1 5
<210> 24
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 24
Gly Tyr Ser Phe Thr Arg Ser Trp
1 5
<210> 25
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 25
Ile Tyr Pro Ser Asp Ser Tyr Thr
1 5
<210> 26
<211> 10
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 26
Thr Asn Tyr Tyr Leu Tyr Tyr Phe Asp Tyr
1 5 10
<210> 27
<211> 12
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 27
Gln Ser Leu Leu Asn Ser Arg Thr Arg Lys Ser Tyr
1 5 10
<210> 28
<211> 3
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 28
Trp Thr Ser
1
<210> 29
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 29
Lys Gln Ser Tyr Asn Leu Phe Thr
1 5
<210> 30
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 30
Gly Tyr Thr Phe Thr Asp Tyr Asn
1 5
<210> 31
<211> 8
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 31
Phe Tyr Pro Tyr Asn Gly Gly Thr
1 5
<210> 32
<211> 12
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 32
Ala Arg Asn His Tyr Tyr Tyr Tyr Ala Met Asp Tyr
1 5 10
<210> 33
<211> 12
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 33
Gln Ser Leu Leu Asn Ser Arg Thr Arg Lys Asn Tyr
1 5 10
<210> 34
<211> 9
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 34
Lys Gln Ser Tyr Asn Leu Pro Trp Thr
1 5
<210> 35
<211> 123
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 35
Glu Val Gln Leu Glu Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Glu
1 5 10 15
Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30
Gly Met Asn Trp Val Lys Gln Ala Pro Gly Lys Ala Leu Lys Trp Met
35 40 45
Gly Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe
50 55 60
Lys Gly Arg Phe Ala Tyr Ser Leu Glu Ala Thr Ala Asn Thr Ala Tyr
65 70 75 80
Leu Gln Ile Tyr Asn Leu Lys Asn Glu Asp Thr Ala Thr Tyr Phe Cys
85 90 95
Ala Arg Ser Gly Arg Tyr Thr Arg Pro Leu Tyr Tyr Ile Met Asp Phe
100 105 110
Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120
<210> 36
<211> 111
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 36
Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15
Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30
Gly Asn Ser Tyr Met Asn Trp His Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45
Lys Leu Leu Ile Tyr Gly Ala Ser Asn Leu Glu Ser Gly Ile Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65 70 75 80
Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn
85 90 95
Glu Asp Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 37
<211> 116
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 37
Glu Val Gln Leu Glu Glu Ser Gly Ala Glu Leu Val Arg Ser Gly Ala
1 5 10 15
Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Phe Asn Asp Tyr
20 25 30
Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile
35 40 45
Gly Trp Ile Asp Pro Glu Asn Gly Asp Thr Glu Tyr Ala Pro Lys Phe
50 55 60
Gln Val Lys Ala Thr Met Thr Ala Asp Thr Ser Ser Asn Thr Ala Tyr
65 70 75 80
Leu His Leu Ser Ser Leu Ala Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Asn Thr Pro Thr Glu Asp Met Asp Tyr Trp Gly Gln Gly Thr Ser Val
100 105 110
Thr Val Ser Ser
115
<210> 38
<211> 112
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 38
Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly
1 5 10 15
Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Phe Asn Ser
20 25 30
Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Gly Ser Gly Val
50 55 60
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Lys Gln
85 90 95
Ser Tyr Asn Leu Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105 110
<210> 39
<211> 118
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 39
Glu Val Lys Leu Gln Glu Ser Gly Ala Glu Leu Val Met Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Ala Ile Asp Thr Ser Asp Ser Tyr Thr Ser Tyr Asn Gln Lys Phe
50 55 60
Lys Gly Lys Ala Thr Leu Thr Val Asp Glu Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Lys Ala Leu Ser Gly Tyr Phe Asp Val Trp Gly Ala Gly Thr
100 105 110
Thr Val Thr Val Ser Ser
115
<210> 40
<211> 106
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 40
Asp Ile Val Leu Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15
Gly Lys Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Ile Tyr Lys Tyr
20 25 30
Ile Ala Trp Tyr Gln His Lys Pro Gly Lys Gly Pro Arg Leu Leu Ile
35 40 45
His Tyr Thr Ser Thr Leu Gln Pro Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Arg Asp Tyr Ser Phe Ser Ile Ser Asn Leu Glu Pro
65 70 75 80
Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu Arg Thr
85 90 95
Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 41
<211> 115
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 41
Glu Val Lys Leu Gln Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln
1 5 10 15
Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Thr Tyr
20 25 30
Gly Val Ser Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45
Gly Ile Ile Trp Gly Asp Gly Thr Thr Ile Tyr Gln Ser Gly Leu Ile
50 55 60
Ser Arg Leu Ser Ile Ser Lys Asp Asp Ser Lys Ser Gln Val Phe Leu
65 70 75 80
Lys Leu Ser Ser Leu Gln Thr Asp Asp Thr Ala Thr Tyr Tyr Cys Ala
85 90 95
Lys His Tyr Phe Val Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr
100 105 110
Val Ser Ser
115
<210> 42
<211> 112
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 42
Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly
1 5 10 15
Glu Lys Val Thr Met Asn Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30
Arg Ile Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Lys Gln
85 90 95
Ser Tyr Asn Leu Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105 110
<210> 43
<211> 126
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 43
Glu Val Gln Leu Gln Gln Ser Gly Ala Val Leu Val Arg Pro Gly Asp
1 5 10 15
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Arg Ser
20 25 30
Trp Ile Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Asn Ile Tyr Pro Ser Asp Ser Tyr Thr Asn Tyr Asn Gln Lys Phe
50 55 60
Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Gln Leu Arg Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Thr Asn Tyr Tyr Leu Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Thr
100 105 110
Leu Thr Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Val Tyr
115 120 125
<210> 44
<211> 121
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 44
Asp Ile Val Leu Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Thr Gly
1 5 10 15
Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30
Arg Thr Arg Lys Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Ser Pro Lys Leu Leu Ile Tyr Trp Thr Ser Ile Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Thr Gly Asn Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Lys Gln
85 90 95
Ser Tyr Asn Leu Phe Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
100 105 110
Arg Ala Asp Ala Ala Pro Thr Val Ser
115 120
<210> 45
<211> 119
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 45
Gln Val Lys Leu Gln Glu Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Asn Met His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45
Gly Tyr Phe Tyr Pro Tyr Asn Gly Gly Thr Gly Tyr Lys Gln Lys Phe
50 55 60
Lys Ser Lys Ala Thr Leu Thr Val Asp Asn Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asn His Tyr Tyr Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Ser Val Thr Val Ser Ser
115
<210> 46
<211> 113
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 46
Asp Ile Val Met Thr Gln Thr Pro Ser Ser Leu Ala Val Ser Ala Gly
1 5 10 15
Glu Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser
20 25 30
Arg Thr Arg Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45
Ser Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60
Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80
Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Lys Gln
85 90 95
Ser Tyr Asn Leu Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
100 105 110
Lys
<210> 47
<211> 330
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 47
Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly
1 5 10 15
Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr
20 25 30
Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu
50 55 60
Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile
65 70 75 80
Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys
85 90 95
Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys
100 105 110
Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro
115 120 125
Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys
130 135 140
Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp
145 150 155 160
Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg
165 170 175
Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln
180 185 190
His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn
195 200 205
Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly
210 215 220
Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu
225 230 235 240
Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met
245 250 255
Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu
260 265 270
Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe
275 280 285
Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn
290 295 300
Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr
305 310 315 320
Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
325 330
<210> 48
<211> 106
<212> PRT
<213> 2 Ambystoma laterale x Ambystoma jeffersonianum
<400> 48
Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln
1 5 10 15
Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr
20 25 30
Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln
35 40 45
Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr
50 55 60
Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg
65 70 75 80
His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro
85 90 95
Ile Val Lys Ser Phe Asn Arg Asn Glu Cys
100 105
